Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have been given an average rating of “Moderate Buy” by the fourteen ratings firms that are presently covering the firm, Marketbeat reports. Four analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $70.22.

Several research analysts recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Guggenheim lowered shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, December 16th. Wells Fargo & Company lifted their price target on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Wedbush reissued an “outperform” rating and issued a $84.00 price objective on shares of Keros Therapeutics in a research report on Thursday, November 7th. Finally, Scotiabank reduced their price objective on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a report on Thursday.

Keros Therapeutics Price Performance

Shares of NASDAQ:KROS opened at $10.52 on Friday. The firm’s 50-day moving average is $38.65 and its two-hundred day moving average is $47.61. Keros Therapeutics has a 1 year low of $9.77 and a 1 year high of $73.00. The firm has a market capitalization of $426.17 million, a PE ratio of -2.02 and a beta of 1.43.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The business had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm’s quarterly revenue was up 4750.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.33) EPS. Analysts expect that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Institutional Investors Weigh In On Keros Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers increased its position in shares of Keros Therapeutics by 20.6% during the second quarter. Rhumbline Advisers now owns 41,638 shares of the company’s stock worth $1,903,000 after purchasing an additional 7,111 shares in the last quarter. Arizona State Retirement System increased its position in Keros Therapeutics by 16.3% during the second quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock worth $369,000 after buying an additional 1,130 shares during the period. Quest Partners LLC lifted its stake in Keros Therapeutics by 23,945.0% in the second quarter. Quest Partners LLC now owns 4,809 shares of the company’s stock valued at $220,000 after buying an additional 4,789 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Keros Therapeutics by 24.9% in the second quarter. American Century Companies Inc. now owns 298,170 shares of the company’s stock valued at $13,626,000 after acquiring an additional 59,364 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in shares of Keros Therapeutics during the second quarter worth approximately $654,000. 71.56% of the stock is owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.